



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref. No.: ADL/SE/2017-2018

Date: 24th May, 2017

To, Department of corporate service, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. <u>BSE CODE - 524348</u> BSE ID - AARTIDRUGS	To, National Stock Exchange of India Limited, "Exchange Plaza", Bandra - Kurla Complex, Bandra (E), Mumbai - 400051. <u>NSE SYMBOL: AARTIDRUGS</u>
---	--

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 24th May, 2017.

This is for your information and records.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

Adhish P. Patil
Chief Financial Officer





Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: audit@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Press release for Mar'17:

March quarter has shown good demand growth in export markets recording the value growth of around 5% and volume growth of around 20% in exports. Lower production due to forced shutdown of couple of units led to lower supply and in turn decline in domestic sales. All facilities are running as of now and company expects higher growth in future.

Consolidated Profit after tax for the quarter ended Mar'17 is 20.73 crores, up by 11.51% due to better gross contributions and reduction in interest cost. Consolidated EBITDA for the quarter ended Mar'17 is 47.28 crores, up by 3.34%. Debt/Equity ratio came down to 1.13 as of Mar'17 as compared to 1.33 as of Mar'16.

Company will be inviting USFDA for re-inspection very soon. Same facility was inspected by EDQM/ European authority in Nov'16 and was recently approved for European market. Recently, Company got the approval for marketing authorization of Zolpidem tablets in UK and Ireland. Company is investing in greener technologies to improve and further reduce the effluent streams, slowly moving towards zero organic effluent discharge mode. Recently, Central Government of India has granted relief in terms of provisional anti-dumping duty to one of our products, which will help to compete against Chinese imports.

For Aarti Drugs Limited

Adhish P. Patil

Chief Financial Officer

